A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation
This study is testing a new experimental drug, WSD0922-FU, for patients with a specific type of non-small cell lung cancer. It is designed for people whose cancer has continued to grow even after taking the standard treatment called Osimertinib.
You may be eligible if you are at least 18 years old and have been diagnosed with advanced lung cancer that has developed a specific mutation called C797S. Your doctor will confirm if your cancer has progressed while on your first-line therapy and ensure you are healthy enough to start a new treatment.
Participants will receive the experimental drug WSD0922-FU at one of the two study-defined dosage levels. You will be closely monitored by a medical team to see how your body responds to the treatment and to keep track of any potential side effects.
This study is currently recruiting volunteers and is taking place in Oxnard, California; Weston, Florida; and Detroit, Michigan. Please talk to your oncologist to see if these locations are accessible for you.
- 1The study focuses on patients who have stopped responding to their first-line Osimertinib treatment.
- 2Participation is strictly voluntary and requires a full understanding of the trial details through an informed consent process.
- 3This is a Phase 2 trial, meaning researchers are looking to see how well the new medication works for this specific group of patients.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.